Publication | Closed Access
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
1.2K
Citations
32
References
2001
Year
The comparable efficacy, favorable safety profile, and convenient dosing support the role of PLD as a valuable treatment option in this patient population.
| Year | Citations | |
|---|---|---|
Page 1
Page 1